AU5541094A - Compositions and methods for modifying the regulatory activity of tgf-beta - Google Patents

Compositions and methods for modifying the regulatory activity of tgf-beta

Info

Publication number: AU5541094A
Authority: AU; Australia
Prior art keywords: tgf; beta; modifying; compositions; methods
Prior art date: 1992-10-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU55410/94A

Inventor

Carmelo Bernabeu

Sela Cheifetz

Michelle Letarte

Joan Massague

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

HSC Research and Development LP

Consejo Superior de Investigaciones Cientificas CSIC

Memorial Sloan Kettering Cancer Center

Original Assignee

HSC Research and Development LP

Consejo Superior de Investigaciones Cientificas CSIC

Memorial Sloan Kettering Cancer Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-30

Filing date

1993-10-26

Publication date

1994-05-24

1992-10-30 Priority claimed from US07/968,953 external-priority patent/US5830847A/en

1993-10-26 Application filed by HSC Research and Development LP, Consejo Superior de Investigaciones Cientificas CSIC, Memorial Sloan Kettering Cancer Center filed Critical HSC Research and Development LP

1994-05-24 Publication of AU5541094A publication Critical patent/AU5541094A/en

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title 1
230000001105 regulatory effect Effects 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU55410/94A 1992-10-30 1993-10-26 Compositions and methods for modifying the regulatory activity of tgf-beta Abandoned AU5541094A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US96895492A	1992-10-30	1992-10-30
US07/968,953 US5830847A (en)	1992-10-30	1992-10-30	Soluble TGF-β-binding endoglin polypeptides and homodimers
US968954		1992-10-30
US968953		1992-10-30
PCT/US1993/010307 WO1994010187A1 (en)	1992-10-30	1993-10-26	COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)

Publications (1)

Publication Number	Publication Date
AU5541094A true AU5541094A (en)	1994-05-24

Family

ID=27130519

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU55410/94A Abandoned AU5541094A (en)	1992-10-30	1993-10-26	Compositions and methods for modifying the regulatory activity of tgf-beta

Country Status (5)

Country	Link
EP (1)	EP0667870A4 (en)
JP (1)	JPH08504577A (en)
AU (1)	AU5541094A (en)
CA (1)	CA2147754A1 (en)
WO (1)	WO1994010187A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
AU688409B2 (en) *	1993-11-19	1998-03-12	University Of Sydney, The	A method for preventing or controlling cataract
JPH09505057A (en) *	1993-11-19	1997-05-20	ザ・ユニバーシティ・オブ・シドニー	Methods to prevent or control cataract
CA2156767A1 (en) *	1994-08-25	1996-02-26	Kenichi Matsunaga	Binding agent for growth factor
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US20020169122A1 (en) *	2001-02-23	2002-11-14	Wyeth	Chondrogenic potential of human bone marrow-derived CD105+ cells by BMP
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
KR101245983B1 (en)	2004-03-31	2013-06-28	제넨테크, 인크.	Humanized anti-TGF-beta antibodies
JP5602365B2 (en)	2005-10-25	2014-10-08	ザ・ジョンズ・ホプキンス・ユニバーシティ	Methods and compositions for treating Marfan syndrome and related diseases.
EP1998810A4 (en)	2006-03-13	2009-09-02	Univ Johns Hopkins	INCREASE IN ENDOTHELIAL THROMBORISISTANCE
CN104645328A (en)	2006-10-03	2015-05-27	建新公司	Use of TGF-BETA antagonists to treat infants at risk of developing bronchopulmonary dysplasia
US8642031B2 (en)	2006-11-02	2014-02-04	Acceleron Pharma, Inc.	Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US8455428B2 (en)	2006-11-02	2013-06-04	Acceleron Pharma, Inc.	ALK1 receptor and ligand antagonist and uses thereof
US10059756B2 (en)	2006-11-02	2018-08-28	Acceleron Pharma Inc.	Compositions comprising ALK1-ECD protein
TW201609138A (en)	2008-05-02	2016-03-16	艾西利羅製藥公司	Methods and compositions for modulating angiogenesis and pericyte composition
US8956868B2 (en)	2010-12-27	2015-02-17	Lsip, Llc	Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
AU2012245439B2 (en) *	2011-04-20	2017-04-06	Acceleron Pharma, Inc.	Endoglin polypeptides and uses thereof
EP2737083A1 (en)	2011-07-27	2014-06-04	INSERM (Institut National de la Santé et de la Recherche Scientifique)	Methods for diagnosing and treating myhre syndrome
IN2014DN03049A (en)	2011-10-26	2015-05-15	Seattle Childrens Res Inst
JP6218229B2 (en)	2011-12-28	2017-10-25	京都府公立大学法人	Normalization of corneal endothelial cell culture
CA2928708A1 (en)	2013-10-25	2015-04-30	Acceleron Pharma, Inc.	Endoglin peptides to treat fibrotic diseases
PL3064222T3 (en)	2013-10-31	2021-04-19	Kyoto Prefectural Public University Corporation	Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2016187312A1 (en)	2015-05-18	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection

1993
- 1993-10-26 AU AU55410/94A patent/AU5541094A/en not_active Abandoned
- 1993-10-26 CA CA002147754A patent/CA2147754A1/en not_active Abandoned
- 1993-10-26 WO PCT/US1993/010307 patent/WO1994010187A1/en not_active Application Discontinuation
- 1993-10-26 EP EP94900408A patent/EP0667870A4/en not_active Withdrawn
- 1993-10-26 JP JP6511285A patent/JPH08504577A/en active Pending

Also Published As

Publication number	Publication date
WO1994010187A1 (en)	1994-05-11
JPH08504577A (en)	1996-05-21
EP0667870A1 (en)	1995-08-23
CA2147754A1 (en)	1994-05-11
EP0667870A4 (en)	1998-04-01

Publication	Publication Date	Title
AU5541094A (en)	1994-05-24	Compositions and methods for modifying the regulatory activity of tgf-beta
AU3469893A (en)	1993-08-03	Hydrogel compositions and structures made from same
AU3691793A (en)	1993-10-21	Gas well treatment compositions and methods
AU4251993A (en)	1993-12-13	Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
AU3575193A (en)	1993-09-13	S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
AU3684293A (en)	1993-10-21	Disinfectant compositions
AU3708093A (en)	1993-11-04	Processes for the preparation of amylase inhibitor
AU6847894A (en)	1995-01-17	Method for the improvement of wound healing and compositions therefor
AU4896090A (en)	1990-08-16	Insecticide treatment and compositions therefor
AU5100393A (en)	1994-04-26	Diindolo compounds and pharmaceutical compositions containing them
AU4520893A (en)	1994-01-31	Sterilization process and composition
AU3801893A (en)	1993-12-13	Insecticide compositions
AU5833194A (en)	1994-07-19	Deodorant compositions
AU5813894A (en)	1994-07-19	Deodorant composition
AU4468093A (en)	1994-02-24	Composition and methods for the generation of bone
AU4563093A (en)	1994-01-31	Echographic contrast agent composition
AU3630695A (en)	1996-03-29	Semi-synthetic lipopeptides, compositions containing said lipopeptides, and methods of use
AU5460294A (en)	1994-06-22	Methods of catalytic photooxidation
AU662651B2 (en)	1995-09-07	Sulfamoyltriazole derivative and bactericide containing the same as active ingredient
AU5847694A (en)	1994-07-04	Chlorofluoroether compositions and preparation thereof
AU3318293A (en)	1993-08-26	Washable dye-containing composition
AU5186093A (en)	1994-06-02	Synergistic mixture
AU5371694A (en)	1994-05-24	Use of the tarchonanthus camphoratus
AU649294B2 (en)	1994-05-19	Phosphate esters and compositions containing them
AU5220893A (en)	1994-06-23	Substituted N-hydroxycinnamamides, processes for their preparation, compositions containing them, and their use